Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.
There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.
BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.
“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”
In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.
In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.
The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.
“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”
This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.
About Ebola Sudan and Marburg
Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.
Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.
For media inquiries:
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314bTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Innofactor Plc: Share Repurchase 6.2.20236.2.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 6.2.2023Innofactor Plc: Share Repurchase 6.2.2023In the Helsinki Stock ExchangeTrade date 6.2.2023Bourse trade BuyShare IFA1VAmount 5,950SharesAverage price/ share 1.1700EURTotal cost 6,961.50EURInnofactor Plc now holds a total of 1 377 186 sharesincluding the shares repurchased on 6.2.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_6.2_trades
Irish MedTech Company Medihive Receives €7 Million Investment6.2.2023 17:00:00 CET | Press release
The business is now valued at €62 million following the investment. Medihive includes Ireland's largest online doctor service WebDoctor.ie. The investment will be used to fuel international growth, drive R&D innovation and accelerate healthcare software developments. Medihive will recruit up to 42 key hires across sales, engineering, doctors and marketing departments, adding to the 130 people already working with the company. DUBLIN, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medihive, Ireland's award-winning health technology platform, which includes Webdoctor.ie, has secured an investment from ResMed, an international leader in digital health and cloud-connected medical device innovation, as well as existing shareholders including VentureWave Capital. The investment now values the business at €62 million. Medihive is a software company built to transform medical processes that don't work so patients can benefit from healthcare that does work. The business provides sophisticated software and c
Icelandair: Traffic Data January 20236.2.2023 16:59:28 CET | Press release
In January 2023, Icelandair’s passengers were 210 thousand, compared to 113 thousand in January last year. Capacity in January was 93% of January 2020 levels, the last normal operating January before the pandemic, and 79% of 2019 levels. Passengers on international flights were 191 thousand, compared to 102 thousand in January 2022, an increase of 88%. Passengers to Iceland were 75 thousand and from Iceland 47 thousand. Via passengers were around 69 thousand. On-time performance on international flights was 75%. On time performance and passenger numbers were affected by weather related disruptions in January. The load factor on international flights improved significantly from 59.5% in January 2022 to 74.6% in January this year. Passengers on domestic flights were 18,500, compared to around 12 thousand in January 2022. On time performance was 84%. Load factor on domestic flights was 72.4%. Weather in Iceland caused disruption in the domestic network in January, affecting on time perfor
Acronis builds on partner momentum with Alex Ruslyakov named a 2023 CRN Channel Chief6.2.2023 16:05:00 CET | Press release
Acronis #CyberFit Partner Program kicks off 2023 with new innovations to fuel rapid growth and global expansion BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Today, Acronis is honored to announce that CRN®, a brand of The Channel Company, has again recognized Alex Ruslyakov on its 2023 Channel Chiefs list. Acronis’ partner programs have seen tremendous growth over the past year, and Ruslyakov's spot on this year’s list further signifies the program's continued momentum. Acronis has focused heavily on improving partner services and programs over the last year. In 2022, more than 3,500 new service providers joined Acronis’ #CyberFit Partner Program – consisting of service providers, resellers, developers and ISVs, OEM, and affiliate partners. This large number of new registrants is a testament to Ruslyakov's leadership, partner-first approach, and his team's effectiveness in helping MSPs accelerate their business growth with robust sales, marketing, and technical support day in an
Floatgen achieves continuous capacity factor of nearly 60%6.2.2023 16:03:30 CET | Press release
BW Ideol is pleased to announce continuously strong operational results from its 5-year-old Floatgen demonstrator, showing a capacity factor of nearly 60% over the last three months and a production of 25GWh since its 2018 commissioning. France’s first and only floating wind turbine continues to prove its reliable performance capabilities and delivered an average capacity factor of 59.2% over a 3-month period ranging from November 2022 to January 2023. The 25 GWh-milestone was reached just after the major Atlantic storm Gerard in late January. The Floatgen turbine, mounted on BW Ideol’s patented Damping Pool® foundation, handled wind speeds up to 37.30 metres per second (equivalent to 134 km/h) and up to 5.5 metres of significant wave height (equivalent to around 10.5 meters maximum wave height). “Floatgen – one of the few floating wind turbines currently in operation across the globe – continues to deliver outstanding results in terms of reliability, efficiency and production. It keep